Bubs Australia Limited (ASX:BUB)
Australia · Delayed Price · Currency is AUD | Market Cap | 78.68M -39.3% |
| Revenue (ttm) | 111.86M +9.1% |
| Net Income | -4.62M |
| EPS | -0.01 |
| Shares Out | 894.13M |
| PE Ratio | n/a |
| Forward PE | 30.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,751,311 |
| Open | 0.0910 |
| Previous Close | 0.0910 |
| Day's Range | 0.0880 - 0.0910 |
| 52-Week Range | 0.0760 - 0.1650 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 0.17 (+93.18%) |
| Earnings Date | Aug 27, 2026 |
About Bubs Australia
Bubs Australia Limited, together with its subsidiaries, manufactures and sell infant and adult chilled and powdered goat dairy products in Australia, China, the United States, and internationally. The company provides goat and cow milk infant formulas, goat milk powder products for adults, and fresh dairy products. It also offers organic baby food, cereals, snacks, and chilled goat milk. In addition, the company holds IP and trademarks. It sells its products under the Bubs and Caprilac brands. The company exports its products. Bubs Australia Li... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BUB stock is "Strong Buy." The 12-month stock price target is $0.17, which is an increase of 93.18% from the latest price.
News
Bubs Australia Transcript: FDA announcement
Permanent FDA authorization for three SKUs establishes a strong position in the U.S. premium infant formula market, enabling expansion, innovation, and long-term investment. The company is now present in nearly 12,000 stores nationwide and is pursuing contract manufacturing opportunities.
Bubs Australia Slides: FDA announcement
Bubs Australia has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Bubs Australia Press release: FDA announcement
Bubs Australia issued a press release on September 9, 2026, disclosing material business information to investors.
Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump
Bubs Australia said on Monday it secured permanent authorisation from the U.S. Food and Drug Administration to sell three infant formula products in the country, putting the stock on course for its ...
Bubs Australia Earnings Call Transcript: H2 2026
Revenue rose 9.2% to AUD 112 million, led by 24% growth in the U.S., now 59% of total sales. Gross margin was 39.8%, with underlying EBITDA at AUD 5.3 million, despite one-off regulatory and logistics costs. Growth is expected to continue, with FDA approval in the U.S. imminent.
Bubs Australia Annual report: H2 2026
Bubs Australia has published its H2 2026 annual report on August 26, 2026.
Bubs Australia Earnings release: H2 2026
Bubs Australia released its H2 2026 earnings on August 26, 2026, summarizing the period's financial results.
Bubs Australia Slides: H2 2026
Bubs Australia has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 26, 2026.
Bubs Australia Annual report: H2 2026
Bubs Australia has published its H2 2026 annual report on August 26, 2026.
Bubs Australia Earnings release: Trading update
Bubs Australia released its earnings on May 29, 2026, summarizing the period's financial results.
Bubs Australia Transcript: Status update
A new executive team is driving disciplined global growth in premium infant nutrition, with upgraded FY26 revenue guidance and strong brand positioning in Australia, China, and the U.S. The company is expanding into new markets, investing in supply chain resilience, and shifting marketing to build long-term brand equity with a capital-light, agile model.
Bubs Australia Slides: Status update
Bubs Australia has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Bubs Australia Earnings Call Transcript: H1 2026
Revenue rose 14% year-over-year, led by U.S. expansion and strong China performance. Gross margin exceeded 50%, and FY26 revenue is projected to grow 22%-27%. Key risks include currency volatility, tariffs, and regulatory challenges.
Bubs Australia Quarterly report: H1 2026
Bubs Australia has published its H1 2026 quarterly earnings report on February 26, 2026.
Bubs Australia Slides: H1 2026
Bubs Australia has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
Bubs Australia Earnings release: H1 2026
Bubs Australia released its H1 2026 earnings on February 26, 2026, summarizing the period's financial results.
Bubs Australia Transcript: AGM 2025
The meeting reviewed strong FY 2025 results, with 23% revenue growth and a focus on U.S. market expansion. Strategic priorities include FDA approval, inventory investment, and a 2030 growth plan. Shareholders voted on key resolutions, and leadership addressed questions on China, tariffs, and future opportunities.
Bubs Australia Slides: FY 2025
Bubs Australia has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.
Bubs Australia Earnings release: Q1 2026
Bubs Australia released its Q1 2026 earnings on October 31, 2025, summarizing the period's financial results.
Bubs Australia shares surge on infant formula supply deal with Walmart
Shares of Bubs Australia jumped on Thursday after the company signed a deal to supply its infant formula products to U.S. retail giant Walmart amid a baby food shortage in the world's largest economy.